Journal article · 2022 · Open access

Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314

Merlin Bresinsky, Jessica M. Strasser, Bernadette Vallaster, Peng Liu, William M. McCue, Jessica L. Fuller, Alexander Hubmann, Gurpreet Singh, Kathryn M. Nelson, Matthew E. Cuellar, Carrie M. Wilmot, Barry C. Finzel and 3 more

ACS Pharmacology & Translational Science, 5(1), 20–40 · Published 5 January 2022 · DOI 10.1021/acsptsci.1c00251

Open full textView at the publisherCite this paper

In brief

“Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314” is a 2022 journal article by Merlin Bresinsky and 14 co-authors, published in ACS Pharmacology & Translational Science. OpenAlex counts 18 citations as of 22 November 2026, which puts it in the top 8% of works published in 2022 by citations. It is open access: the full text is free to read at PubMed Central.

Citations
18
Most cited in
2022 (5)
Field-weighted impact
1.02
References
52
Authors
15

Abstract

Alzheimer’s disease (AD) was first described by Alois Alzheimer over 100 years ago, but there is still no overarching theory that can explain its cause in detail. There are also no effective therapies to treat either the cause or the associated symptoms of this devastating disease. A potential approach to better understand the pathogenesis of AD could be the development of selective caspase-2 (Casp2) probes, as we have shown that a Casp2-mediated cleavage product of tau (Δtau314) reversibly impairs cognitive and synaptic function in animal models of tauopathies. In this article, we map out the Casp2 binding site through the preparation and assay of a series of 35 pentapeptide inhibitors with the goal of gaining selectivity against caspase-3 (Casp3). We also employed computational docking methods to understand the key interactions in the binding pocket of Casp2 and the differences predicted for binding at Casp3. Moreover, we crystallographically characterized the binding of selected pentapeptides with Casp3. Furthermore, we engineered and expressed a series of recombinant tau mutants and investigated them in an in vitro cleavage assay. These studies resulted in simple peptidic inhibitors with nanomolar affinity, for example, AcVDV(Dab)D-CHO ( 24 ) with up to 27.7-fold selectivity against Casp3. Our findings provide a good basis for the future development of selective Casp2 probes and inhibitors that can serve as pharmacological tools in planned in vivo studies and as lead compounds for the design of bioavailable and more drug-like small molecules.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bresinsky, M., Strasser, J. M., Vallaster, B., Liu, P., McCue, W. M., Fuller, J. L., Hubmann, A., Singh, G., Nelson, K. M., Cuellar, M. E., Wilmot, C. M., Finzel, B. C., Ashe, K. H., Walters, M. A., & Pockes, S. (2022). Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314. ACS Pharmacology & Translational Science, 5(1), 20–40. https://doi.org/10.1021/acsptsci.1c00251

MLA 9

Bresinsky, Merlin, et al. “Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314.” ACS Pharmacology & Translational Science, vol. 5, no. 1, 2022, pp. 20–40. https://doi.org/10.1021/acsptsci.1c00251.

Chicago

Bresinsky, Merlin, Jessica M. Strasser, Bernadette Vallaster, Peng Liu, William M. McCue, Jessica L. Fuller, Alexander Hubmann, et al. 2022. “Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314.” ACS Pharmacology & Translational Science 5 (1): 20–40. https://doi.org/10.1021/acsptsci.1c00251.

Harvard

Bresinsky, M. et al. (2022) ‘Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314’, ACS Pharmacology & Translational Science, 5(1), pp. 20–40. doi:10.1021/acsptsci.1c00251.

IEEE

M. Bresinsky et al., “Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314,” ACS Pharmacology & Translational Science, vol. 5, no. 1, pp. 20–40, 2022, doi: 10.1021/acsptsci.1c00251.

BibTeX

@article{bresinsky2022structure,
  title     = {{Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314}},
  author    = {Bresinsky, Merlin and Strasser, Jessica M. and Vallaster, Bernadette and Liu, Peng and McCue, William M. and Fuller, Jessica L. and Hubmann, Alexander and Singh, Gurpreet and Nelson, Kathryn M. and Cuellar, Matthew E. and Wilmot, Carrie M. and Finzel, Barry C. and Ashe, Karen H. and Walters, Michael A. and Pockes, Steffen},
  journal   = {ACS Pharmacology \& Translational Science},
  year      = {2022},
  volume    = {5},
  number    = {1},
  pages     = {20--40},
  doi       = {10.1021/acsptsci.1c00251},
  url       = {https://doi.org/10.1021/acsptsci.1c00251}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202255
202344
202422
202522
202655

Its field-weighted citation impact is 1.02: it has been cited 1.02 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • tau cleavage
  • Alzheimer's disease
  • crystal structure
  • molecular docking
  • tauopathy
  • structure-based drug design

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Bresinsky, M., Strasser, J. M., Vallaster, B., Liu, P., McCue, W. M., Fuller, J. L., Hubmann, A., Singh, G., Nelson, K. M., Cuellar, M. E., Wilmot, C. M., Finzel, B. C., Ashe, K. H., Walters, M. A., & Pockes, S. (2022). Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314. ACS Pharmacology & Translational Science, 5(1), 20–40. https://doi.org/10.1021/acsptsci.1c00251

How many times has this paper been cited?

18 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the full text from this page.

Who wrote this paper?

Merlin Bresinsky, Jessica M. Strasser, Bernadette Vallaster, Peng Liu, William M. McCue, Jessica L. Fuller, Alexander Hubmann, Gurpreet Singh, Kathryn M. Nelson, Matthew E. Cuellar, Carrie M. Wilmot, Barry C. Finzel and 3 more.

What is the DOI of this paper?

10.1021/acsptsci.1c00251, permanently at https://doi.org/10.1021/acsptsci.1c00251. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.